Modality
siRNA
MOA
BCMA ADC
Target
JAK2
Pathway
Incretin
Endometrial CaHemophilia A
Development Pipeline
Preclinical
~Dec 2023
→ ~Mar 2025
Phase 1
Jun 2025
→ Nov 2030
Phase 1Current
NCT06621984
2,332 pts·Hemophilia A
2025-06→2030-11·Completed
2,332 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-194.6y awayInterim· Hemophilia A
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Complet…
Catalysts
Interim
2030-11-19 · 4.6y away
Hemophilia A
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06621984 | Phase 1 | Hemophilia A | Completed | 2332 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR |